» Articles » PMID: 25009720

The First 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony Test in Belgium and the Netherlands

Overview
Date 2014 Jul 11
PMID 25009720
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

As the classical first trimester Down syndrome screening (FTS, combination test) has a false-negative rate of 20-25% and > 95% of the abnormal FTS results are false-positive, we evaluated the new Non-Invasive Prenatal Test (NIPT) in Belgium and the Netherlands. The study population consisted of 3000 consecutive pregnancies in Belgium and the Netherlands in which NIPT was performed using the Harmony test. In 57 (1.9%) of the 3000 pregnancies an abnormal NIPT result was found. This included 51 fetuses with trisomy 21, 4 fetuses with trisomy 18 and 2 fetuses with trisomy 13. In 47 of the 57 the NIPT result was confirmed by genetic testing of material obtained by amniocentesis or chorionic biopsy, and no false-positive results were recorded. The false-negative rate as determined on more than 2000 women that had delivered at the time of reporting was low, and so far only 2 false-negative results were reported (one trisomy 18 and one trisomy 21). The failure rate where no NIPT result could be obtained after repeated sampling was 0.90%. In this large clinical series, NIPT using the Harmony test proves to be a very reliable prenatal test to detect fetal trisomies 21, 18 and 13 in maternal blood in Belgium and the Netherlands.

Citing Articles

Isolation and Characterization of Cell-Free DNA from Cerebral Organoids.

Silver B, Brooks A, Gerrish K, Tokar E Int J Mol Sci. 2024; 25(10).

PMID: 38791569 PMC: 11121789. DOI: 10.3390/ijms25105522.


Pluripotent stem cells for target organ developmental toxicity testing.

Wu X, Chen Y, Kreutz A, Silver B, Tokar E Toxicol Sci. 2024; 199(2):163-171.

PMID: 38547390 PMC: 11131012. DOI: 10.1093/toxsci/kfae037.


Reasons for failure of noninvasive prenatal test for cell-free fetal DNA in maternal peripheral blood.

Kong X, Zhang L, Yang R, Zhang H, Ren M, Wang X Mol Genet Genomic Med. 2024; 12(1):e2351.

PMID: 38284448 PMC: 10795076. DOI: 10.1002/mgg3.2351.


Expanding Use of cfDNA Screening in Pregnancy: Current and Emerging Ethical, Legal, and Social Issues.

Parham L, Michie M, Allyse M Curr Genet Med Rep. 2023; 5(1):44-53.

PMID: 38089918 PMC: 10715629. DOI: 10.1007/s40142-017-0113-x.


Cell-free DNA as a potential biomarker of differentiation and toxicity in cardiac organoids.

Silver B, Gerrish K, Tokar E Elife. 2023; 12.

PMID: 37261896 PMC: 10287154. DOI: 10.7554/eLife.83532.


References
1.
Wapner R, Thom E, Simpson J, Pergament E, Silver R, Filkins K . First-trimester screening for trisomies 21 and 18. N Engl J Med. 2003; 349(15):1405-13. DOI: 10.1056/NEJMoa025273. View

2.
Alfirevic Z, Sundberg K, Brigham S . Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev. 2003; (3):CD003252. PMC: 4171981. DOI: 10.1002/14651858.CD003252. View

3.
Loane M, Morris J, Addor M, Arriola L, Budd J, Doray B . Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet. 2012; 21(1):27-33. PMC: 3522199. DOI: 10.1038/ejhg.2012.94. View

4.
Simpson J . Cell-free fetal DNA and maternal serum analytes for monitoring embryonic and fetal status. Fertil Steril. 2013; 99(4):1124-34. DOI: 10.1016/j.fertnstert.2013.02.012. View

5.
Fairbrother G, Johnson S, Musci T, Song K . Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population. Prenat Diagn. 2013; 33(6):580-3. DOI: 10.1002/pd.4092. View